Bad Bet? The Pfizer Pipeline Is A Longshot
Make a commentBy Ed Silverman // October 15th, 2007 // 3:45 pm
At least, that’s what Forbes writes after digesting the news that the drugmaker promoted Martin Mackay to head R&D; hired seasoned entrepreneur Corey Goodman to run a new biotech center, and lured Briggs Morrison from Merck to oversee clinical development. These moves may pan out, but meanwhile, the mag posits that Pfizer’s pipeline is so dry that it has about as much chance of success as Democrats give the White House strategy in Iraq. You can read the full analysis here. (You may have to click on the graphic to read it more easily).